Bachem Holding AG | Balance Sheet

Fiscal year is January-December. All values CHF Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
38,721.00
29,494.00
23,249.00
19,206.00
17,283.00
22,302
Total Accounts Receivable
36,724.00
44,887.00
42,047.00
52,208.00
57,992.00
85,327
Inventories
141,043.00
139,256.00
139,664.00
151,890.00
172,719.00
195,608
Other Current Assets
1,339.00
1,057.00
1,664.00
2,489.00
3,201.00
2,145
Total Current Assets
217,827.00
214,694.00
206,624.00
225,793.00
251,195.00
305,382
Net Property, Plant & Equipment
208,346.00
208,924.00
223,120.00
255,265.00
274,520.00
289,795
Intangible Assets
9,435.00
8,025.00
9,325.00
9,595.00
12,671.00
13,523
Other Assets
320.00
320.00
320.00
320.00
320.00
320
Total Assets
438,777.00
435,013.00
443,832.00
496,509.00
544,655.00
614,700
ST Debt & Current Portion LT Debt
44,717.00
21,207.00
17,146.00
55,134.00
94,746.00
Accounts Payable
7,611.00
11,513.00
14,866.00
19,739.00
17,719.00
Income Tax Payable
2,026.00
2,069.00
4,272.00
3,562.00
2,412.00
Other Current Liabilities
15,235.00
18,793.00
22,555.00
21,066.00
21,340.00
Total Current Liabilities
69,589.00
53,582.00
58,839.00
99,501.00
136,217.00
Long-Term Debt
324.00
149.00
277.00
302.00
188.00
Deferred Taxes
29,577.00
29,101.00
26,910.00
25,806.00
28,129.00
Total Liabilities
102,339.00
85,882.00
90,469.00
131,145.00
170,483.00
Common Equity (Total)
336,438.00
349,131.00
353,363.00
365,364.00
374,172.00
Total Shareholders' Equity
336,438.00
349,131.00
353,363.00
365,364.00
374,172.00
Total Equity
336,438.00
349,131.00
353,363.00
365,364.00
374,172.00
Liabilities & Shareholders' Equity
438,777.00
435,013.00
443,832.00
496,509.00
544,655.00

About Bachem Holding

View Profile
Address
Hauptstrasse 144
Bubendorf Basel-Landschaft (Basle Country) 4416
Switzerland
Employees -
Website http://www.bachem.com
Updated 07/08/2019
Bachem Holding AG is a technology-based biochemical company providing full-service to the pharmaceutical and biotechnology industry. The firm operates through the Europe and North America segments. It specializes in the development of manufacturing processes and the production of peptide-based active pharmaceutical ingredients.